SEARCH

SEARCH BY CITATION

References

  • 1
    Greenlee RT,Murray T,Bolden S,Wingo PA. Cancer statistics, 2000. CA Cancer. J Clin 2000; 50: 733.
  • 2
    Yuan YF,Mendez R,Sahin A,Dai JL. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res 2001; 61: 555861.
  • 3
    Coopman PJ,Do MT,Barth M,Bowden ET,Hayes AJ,Basyuk E,Blancato JK,Vezza PR,McLeskey SW,Mangeat PH,Mueller SC. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 2000; 406: 7427.
  • 4
    Toyama T,Iwase H,Yamashita H,Hara Y,Omoto Y,Sugiura H,Zhang Z,Fujii Y. Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett 2003; 189: 97102.
  • 5
    Endo Y,Uzawa K,Mochida Y,Shiiba M,Bukawa H,Yokoe H,Tanzawa H. Sarcoendoplasmic reticulum Ca(2+) ATPase type 2 downregulated in human oral squamous cell carcinoma. Int J Cancer 2004; 110: 22531.
  • 6
    Onda T,Uzawa K,Endo Y,Bukawa H,Yokoe H,Shibahara T,Tanzawa H. Ubiquitous mitochondrial creatine kinase downregulated in oral squamous cell carcinoma. Br J Cancer 2006; 94: 698709.
  • 7
    Wahi PN. Histological typing of oral and oropharyngeal tumours. International histological classification of tumours, 4th edn. Geneva: World Health Organization, 1971. 928.
  • 8
    Hermanek P,Sobin LH, eds. TNM classification of malignant tumours,4th edn. Berlin: Springer-Verlag, 1987. 1618.
  • 9
    Uzawa K,Suzuki H,Yokoe H,Tanzawa H,Sato K. Mutational state of p16/CDKN2 and VHL genes in squamous-cell carcinoma of the oral cavity. Int J Oncol 1995; 7: 8959.
  • 10
    Yamamoto N,Uzawa K,Yakushiji T,Shibahara T,Noma H,Tanzawa H. Analysis of the ANA gene as a candidate for the chromosome 21q oral cancer susceptibility locus. Br J Cancer 2001; 84: 7549.
  • 11
    Joshi BH,Kawakami K,Leland P,Puri RK. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res 2002; 8: 194856.
  • 12
    Tao DD,Jiang M,Feng YD,Wu JH,Gong JP. Expression of estrogen receptor in different breast cancer cell lines transfected with estrogen receptor plasmid HEGO5 mediated by FuGENE6. Ai Zheng 2004; 23: 116670.
  • 13
    Cho Y,Gorina S,Jeffrey PD,Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 34655.
  • 14
    Tebbutt NC,Giraud AS,Inglese M,Jenkins B,Waring P,Clay FJ,Malki S,Alderman BM,Grail D,Hollande F,Heath JK,Ernst M. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002; 8: 10802.
  • 15
    Saadoun S,Papadopoulos MC,Hara-Chikuma M,Verkman AS. Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 2005; 434: 78692.
  • 16
    Conacci-Sorrell M,Kaplan A,Raveh S,Gavert N,Sakurai T,Ben-Ze'ev A. The shed ectodomain of Nr-CAM stimulates cell proliferation and motility, and confers cell transformation. Cancer Res 2005; 65: 1160512.
  • 17
    Yuan Y,Liu H,Sahin A,Day JL. Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. Int J Cancer 2005; 113: 6549.
  • 18
    Goodman PA,Burkhardt N,Juran B,Tibbles HE,Uckun FM. Hypermethylation of the spleen tyrosine kinase promoter in T-lineage acute lymphoblastic leukemia. Oncogene 2003; 22: 250414.
  • 19
    Wang L,Duke L,Zhang PS,Arlinghaus RB,Symmans WF,Sahin A,Mendez R,Dai JL. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res 2003; 63: 472430.
  • 20
    Mahabeleshwar GH,Kundu GC. Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3′-kinase activity in breast cancer cells. J Biol Chem 2003; 278: 620921.
  • 21
    Moroni M,Soldatenkov V,Zhang L,Zhang Y,Stoica G,Gehan E,Rashidi B,Singh B,Ozdemirli M,Mueller SC. Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res 2004; 64: 734654.
  • 22
    Lu J,Lin WH,Chen SY,Longnecker R,Tsai SC,Chen CL,Tsai CH. Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J Biol Chem 2006; 281: 880614.
  • 23
    Luangdilok S,Box C,Patterson L,Court W,Harrington K,Pitkin L,Rhŷs-Evans P,O-charoenrat P,Eccles S. Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. Cancer Res 2007; 67: 790716.
  • 24
    Yuan Y,Wang J,Li J,Wang L,Li M,Yang Z,Zhang C,Dai JL. Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin Cancer Res 2006; 12: 668795.
  • 25
    Li J,Sidell N. Growth-related oncogene produced in human breast cancer cells and regulated by Syk protein-tyrosine kinase. Int J Cancer 2005; 117: 1420.
  • 26
    Wang S,Ding YB,Chen GY,Xia JG,Wu ZY. Hypermethylation of Syk gene in promoter region associated with oncogenesis and metastasis of gastric carcinoma. World J Gastroenterol 2004; 10: 181518.
  • 27
    Jones PA,Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21: 1637.
  • 28
    Saito Y,Takazawa H,Uzawa K,Tanzawa H,Sato K. Reduced expression of E-cadherin in oral squamous cell carcinoma: relationship with DNA methylation of 5′ CpG island. Int J Oncol 1998; 12: 2938.
  • 29
    Miracca EC,Kowalski LP,Nagai MA. High prevalence of p16 genetic alterations in head and neck tumours. Br J Cancer 1999; 81: 67783.
  • 30
    Shintani S,Nakahara Y,Mihara M,Ueyama Y,Matsumura T. Inactivation of the p14ARF, p15INK4B and p16INK4A genes is a frequent event in human oral squamous cell carcinomas. Oral Oncol 2001; 37: 498504.